Cargando…
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Exploring resistance mechanisms in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line treatment strategies. Here we report a case of emergent MET ampl...
Autores principales: | Zhu, Viola W, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419586/ https://www.ncbi.nlm.nih.gov/pubmed/30881166 http://dx.doi.org/10.2147/LCTT.S190403 |
Ejemplares similares
-
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021) -
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner, Samuel J, et al.
Publicado: (2017) -
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020) -
Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017) -
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)